6 news items
Aptose Announces Results from Annual and Special Meeting of Shareholders
APTO
18 Jun 24
Dan Ferry, Managing DirectorCorporate Communications
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
APTO
14 Jun 24
, Managing DirectorCorporate Communications & Investor Relations617-430-7576201-923-2049Daniel
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
APTO
3 Jun 24
Corporate Communications & Investor Relations
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
APTO
31 May 24
Corporate Communications & Investor Relations
Aptose Reports Results for the First Quarter 2024
APTO
14 May 24
Corporate Communications & Investor Relations617-430-7576201
xgli7p6h08csj4rb1fufyumv
APTO
6 May 24
Communications & Investor Relations617-430-7576201-923-2049Daniel@LifeSciAdvisors.comspietropaolo
- Prev
- 1
- Next